Indian Heart Journal · 2015 · 11 citations · 21 references
MedicineCardiologyPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsAntiplatelet TherapyAntithrombotic TherapyCoronary Artery DiseasePercutaneous Coronary InterventionThrombosisThrombosis PreventionAntiplatelet DrugsAntiplatelet Therapy After Percutaneous Coronary InterventionAntithrombotic Therapy After Stent ImplantationClopidogrel ResistanceCyp2c19 GenotypeCyp2c19 PharmacogeneticsCyp2c19-guided Antiplatelet TherapyGenotype-guided Antiplatelet Therapy
BACKGROUND: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival. Several outcome studies support this view particularly if the patient is to be started on clopidogrel due to the prevalence of clopidogrel resistance. Such guided therapy has reduced the incidence of Major Adverse Cardiac Events (MACE) after stent implantation. METHODS: Between August 2013 and August 2014, 200 patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) were prescribed any one of the anti-platelet medications such as clopidogrel, prasugrel or ticagrelor and offered testing to detect CYP2C19 gene mutations along with a platelet reactivity assay (PRA). Intended outcome was modification of anti-platelet therapy defined as either dose escalation of clopidogrel or replacement of clopidogrel with prasugrel or ticagrelor for the patients in clopidogrel arm, and replacement of ticagrelor or prasugrel with clopidogrel if those patients were non-carrier of mutant genes and also if they demonstrated bleeding tendencies in the ticagrelor and prasugrel arms. CONCLUSION: Clopidogrel resistance was observed to be 16.5% in our study population. PRA was useful in monitoring the efficacy of thienopyridines. By having this test, one can be safely maintained on clopidogrel in non-carriers, or with increased dose of clopidogrel in intermediate metabolizers or with newer drugs such as ticagrelor or prasugrel in poor metabolizers. Patients on ticagrelor and prasugrel identified as non-carriers of gene mutations for clopidogrel metabolism could be offered clopidogrel resulting in economic benefits to the patients. Patients at high risk of bleeding were also identified by the PRA.
21
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin, Richard C. Becker, Andrzej Budaj et al. · New England Journal of Medicine · 2009 · 7.1K citations · Full text
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Steven R. Steinhubl, Peter B. Berger, J. Tift Mann et al. · JAMA · 2002 · 3.1K citations
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Jessica L. Mega, Sandra Close, Stephen D. Wiviott et al. · New England Journal of Medicine · 2008 · 2.5K citations · Full text
Medicine, Cardiology, Pharmacology +17